Alix Ventures
Alix Ventures is an early-stage venture capital firm backing TechBio startups at Pre-Seed, Seed, and Series A stages with $100K-$500K checks, operating the BIOS ecosystem (community, content, and angel syndicate) to source deals and support Life Science founders driving patient impact.
- Company typePrivate
- Founded2020
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Alix Ventures does
Alix Ventures is an early-stage venture capital firm founded in 2020 and headquartered in the San Francisco Bay Area, focused on backing TechBio startups at the intersection of technology and biology that target radical advances in human health. The firm invests at Pre-Seed, Seed, and select Series A stages with $100K-$500K check sizes, reserving 50% of fund capital for follow-on investments of $1-2M (Series A) and $5-10M (Series B). Alix serves early-stage Life Science founders building both therapeutic/diagnostic applications and bio-economy infrastructure, with portfolio companies spanning cell and gene therapy (64x Bio, Strand Therapeutics, Exthymic), synthetic biology (Elegen, Chemify), ADCs (Mythic Therapeutics), precision immunology (Endpoint Health), organoids (Xilis), single-cell platforms (Zafrens), mass cytometry (Teiko), and digital health (Pair Team).
The firm's core proprietary asset is the BIOS Platform — an integrated ecosystem of content (BIOS Medium publication ranked Top VC Writer, BIOS Podcast ranked Top 100 Life Sciences, BIOS Daily Newsletter with 25K+ subscribers), community (BIOS Commons with 1000+ invite-only members), and capital (BIOS Angels, the world's first TechBio angel syndicate). This ecosystem functions as a deal-sourcing and brand-building engine, augmented by a Venture Residency Program that admits 2 fellows per year from 4000+ applicants (~0.1% acceptance rate) with a 100% placement rate into top-tier VC firms and startups. The team consists of 1-10 employees led by Founder & General Partner Chas Pulido (ex-Pareto Life Sciences, Clara Health, Liquid 2 Ventures), Venture Partner Nick Goldner (PhD, founder of Viosera Therapeutics and resistanceBio), and Operating Partner Mark Pulido (former CEO of Novartis Pharmaceuticals USA, McKesson, and ABILITY). Scientific Advisory Board members include Brian Fiske (co-founder/CSO Mythic Therapeutics), Daniel Delubac (COO Xilis), and Jake Becraft (co-founder/CEO Strand Therapeutics).
Alix's revenue model is that of a traditional venture capital fund: management fees on committed capital (typically 2%) plus carried interest on portfolio exits (typically 20%), with no fees charged to portfolio companies for investment. The firm has co-invested alongside tier-1 funds including a16z, Foresite Capital, Viking Global, First Round, Mayfield, 8VC, KdT, Founders Fund, HOF Capital, Northpond, Mubadala, GV, LSP, Felicis, and Two Sigma. Portfolio companies have collectively raised $850M+ in capital and reached a $2.5B+ aggregate valuation, creating 700+ jobs across the portfolio. Alix's go-to-motion is community-led content marketing at the top of the funnel (BIOS content and community), followed by a structured 3-meeting investment process over 3-4 weeks for diligence and decision-making.
Alix Ventures firmographics
Firmographics- Name
- Alix Ventures
- Legal name
- Alix Ventures
- Website
- https://alix.vc
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Alix Ventures is an early-stage venture capital firm backing TechBio startups at Pre-Seed, Seed, and Series A stages with $100K-$500K checks, operating the BIOS ecosystem (community, content, and angel syndicate) to source deals and support Life Science founders driving patient impact.
- Ownership category
- akta.pro rank
Alix Ventures industry classification
Industry- Product category
- Life Science Venture Capital
- NAICS
- Portfolio Management and Investment Advice (523940), Other Investment Pools and Funds (5259)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Early-Stage Venture Capital (Series A/B) (FSANAAAB)
- akta.pro secondary industries
- Healthcare & Life Sciences Growth Equity (FSANACAB), Micro-VC & Angel Funds (FSANAAAI)
Keywords
Where Alix Ventures is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Alix Ventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Others
Revenue model
- Venture Capital Returns / Portfolio Equity: Alix Ventures generates returns through equity ownership in early-stage Life Science portfolio companies. As a VC firm, revenue is realized through exits (acquisitions, IPOs) of portfolio companies. The firm reserves 50% of its fund for follow-on investments and targets $1–2M SPVs for Series As and $5–10M for Series Bs, indicating significant capital reserved to maintain/increase ownership through subsequent rounds.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Seed Investment: $100K–$500K per company |
| Other | Multi-year contract | Follow-on Reserve: 50% of fund for portfolio companies |
| Other | Annual | Venture Fellowship Stipend: $5,000 for 1-year part-time program |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels7 records
Alix Ventures product offering
Product offeringCore offering
Alix Ventures provides Pre-Seed, Seed, and selective Series A equity investments ($100K–$500K initial checks) to early-stage Life Science and TechBio startups, reserving 50% of fund capital for follow-on participation in $1–2M Series A and $5–10M Series B SPVs. Portfolio companies receive value-add services including customer introductions, fundraising support, hiring assistance, KPI guidance, and access to the BIOS ecosystem (BIOS Commons community of 1000+ members, BIOS Angels syndicate, BIOS Medium, BIOS Podcast, BIOS Daily Newsletter with 25K+ subscribers) along with operating support from a 5x CEO Operating Partner.
Product overview
Alix Ventures is an early-stage Life Science venture capital firm that operates as a unified platform combining investment services with community and content products. The core offering centers on BIOS, a comprehensive TechBio ecosystem comprising BIOS Community (1000+ member invite-only network), BIOS Angels (world's first TechBio angel syndicate), BIOS Medium (top VC writer content platform), BIOS Podcast (top 100 podcast), and BIOS Daily Newsletter (25K+ subscribers). These products work together to unite Life Science innovators, facilitate investment opportunities, and drive patient impact. Alix also offers a Venture Residency Program for aspiring VC professionals and produces thematic research reports covering frontier biotechnology areas. The firm's investment portfolio spans 18+ companies including Xilis, Elegen, 64x Bio, Mythic, Endpoint Health, Zafrens, Teiko, and others focused on cell therapy, gene therapy, synthetic biology, and precision medicine.
Differentiator
Problem solved
Functional benefit
Brands
- BIOS: Content and community platform for Life Science startup innovation. Includes BIOS Medium, BIOS Podcast, BIOS Daily Newsletter, BIOS Angels (angel investing syndicate), and BIOS Commons (invite-only community with 1000+ members).
Products and services
- Pre-Seed, Seed, and Series A Venture Capital Investments Equity capital investments of $100K–$500K at Pre-Seed, Seed, and select Series A stages for early-stage Life Science and TechBio startups, typically as first institutional check-in, with follow-on capital reserved for portfolio companies.
- BIOS Community An invite-only community platform (BIOS Commons with 1000+ members) connecting Life Science startup innovators with mentors, industry experts, and investors to foster innovation and drive patient impact.
- BIOS Angels The world's first TechBio angel investing syndicate, enabling angel investors to participate in early-stage Life Science startup investments alongside the firm's portfolio.
- BIOS Medium A thought leadership content platform (Top VC Writer on Medium) featuring articles, founder spotlights, and industry insights for the Life Science ecosystem.
- BIOS Podcast A top-ranked podcast (Top 100 Life Sciences on Spotify) featuring interviews with Life Science industry leaders covering biotechnology, healthcare innovation, and startup ecosystems.
- BIOS Daily Newsletter A daily newsletter with 25K+ subscribers delivering insights, news, and analysis on the evolving Life Science startup ecosystem.
- Venture Residency Program A 1-year paid part-time (~15 hours/week) residency program for aspiring Life Science VC professionals and biotech entrepreneurs, offering a $5,000 stipend and reporting a 100% placement rate into VC and startup roles upon completion.
- Thematic Research Reports In-depth market research reports covering 18+ TechBio focal areas including Cell & Gene Therapy, Synthetic Biology, AI-Enabled Drug Discovery, CRISPR Therapeutics, Organoids, Viral Vector Manufacturing, Gene Circuits, Precision Immunology, Antibodies, ADCs, Protein Degradation, Circular RNA, Non-Viral Gene Delivery, and Spatial Transcriptomics.
Quantifiable outcome
- Portfolio companies have raised $850M+ in total capital and created 700+ jobs with a collective portfolio value exceeding $2.5B.
- +3 more outcomes
Companies that use Alix Ventures
Customer profileNamed customers8 records
Segments3 records
Ideal customer profiles2 records
Alix Ventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Alix Ventures partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Cleveland CliniccoreOne of 60+ hospital clinical partnerships supporting Endpoint Health's data-driven precision immunology platform. Powers the biomarker and companion diagnostic development through real-world clinical data.
- Vanderbilt University Medical CentercoreOne of 60+ hospital clinical partnerships supporting Endpoint Health's platform. Contributes clinical data for biomarker discovery and precision companion diagnostic development.
- Harvard Wyss Institute for Biologically Inspired Engineeringcore64x Bio is a spinout of Harvard's Wyss Institute, co-founded by George Church. This academic partnership is the intellectual origin of the company's high-throughput discovery platform for viral vector manufacturing optimization.
- George Church (Harvard/MIT)coreGeorge Church, renowned geneticist at Harvard and MIT, co-founded 64x Bio with Lex Rovner, Jeff Way, David Thompson, Pamela Silver. Church's lab at Harvard is the institutional birthplace of the company.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
Alix Ventures competitors and assessment
Company assessmentDirect peers
- KdT Ventures: Early-stage fund explicitly focused on TechBio at the intersection of technology and biology, investing at pre-seed/seed. Frequently co-invests alongside Alix (e.g., Elegen, Circularis) and shares the same founder-focused, scientific-bar approach.
- Civilization Ventures: Early-stage Life Sciences VC investing across digital health, diagnostics, and tech-enabled bio. Co-invested with Alix in Teiko and shares a similar founder-supportive, sector-specialist thesis.
- Lifeforce Capital: Early-stage Life Sciences and healthcare VC investing at the intersection of biology and technology. Co-invested with Alix in 64x Bio and Mythic Therapeutics, with overlapping focus areas in CGT and oncology platforms.
- Prime Movers Lab: Early-stage fund backing breakthrough scientific discoveries across life sciences, energy, and tech. Co-invested with Alix in Zafrens, with comparable pre-seed/seed check sizes and deep-tech orientation.
- Cantos Ventures: Early-stage venture firm with explicit focus on TechBio and frontier science companies. Co-invested with Alix in Circularis and 64x Bio; multiple Cantos team members are Alix Venture Residency alumni.
- Pioneer Fund: Early-stage fund focused on biotech and technology startups founded by Alix venture partner Nick Goldner prior to joining Alix. Similar seed-stage Life Sciences investment thesis.
Broad incumbents
- Lux Capital: Established venture firm with a significant TechBio and frontier-science practice investing across stages. Larger and more diversified than Alix, but operates in overlapping sectors (synthetic biology, neuroscience, space-bio convergence).
- Andreessen Horowitz (a16z Bio + Health): Tier-1 venture firm with a dedicated Bio + Health franchise investing across therapeutics, digital health, and TechBio. Recurring Alix co-investor in companies like Elegen and endpoint-health adjacent deals; operates at materially larger fund and check sizes.
- ARCH Venture Partners: Pioneering Life Sciences and physical sciences venture firm founding and building companies from inception. Represents the large, established end of the Life Sciences VC market where Alix portfolio companies graduate for Series B and beyond.
Regional players
- Liquid 2 Ventures: Early-stage venture firm (founded by Joe Montana) where Alix founder Chas Pulido began his HC/LS investing career. Strong US focus on healthcare and consumer, with a similar pre-seed/seed orientation and overlapping founder-network reach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Alix Ventures social profiles
Digital presenceAlix Ventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alix Ventures leadership team
Management profileNumber of profiles
Profiles6 records
Alix Ventures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alix Ventures M&A and investment
M&A and investmentM&A
Investments19 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alix Ventures
What does Alix Ventures do?
Alix Ventures provides Pre-Seed, Seed, and selective Series A equity investments ($100K–$500K initial checks) to early-stage Life Science and TechBio startups, reserving 50% of fund capital for follow-on participation in $1–2M Series A and $5–10M Series B SPVs. Portfolio companies receive value-add services including customer introductions, fundraising support, hiring assistance, KPI guidance, and access to the BIOS ecosystem (BIOS Commons community of 1000+ members, BIOS Angels syndicate, BIOS Medium, BIOS Podcast, BIOS Daily Newsletter with 25K+ subscribers) along with operating support from a 5x CEO Operating Partner.
Is Alix Ventures a public or private company?
Alix Ventures is a private company. It is classified as venture growth investor backed and is currently operating.
When was Alix Ventures founded?
Alix Ventures was founded in 2020. It employs 1 to 10 people.
Where is Alix Ventures based?
Alix Ventures is headquartered in San Francisco, United States, in the North America region.
How does Alix Ventures make money?
One revenue line is on record: venture Capital Returns / Portfolio Equity.
Who are Alix Ventures's main competitors?
Direct peers on record are KdT Ventures, Civilization Ventures, Lifeforce Capital, Prime Movers Lab, Cantos Ventures and Pioneer Fund. Broad incumbents are Lux Capital, Andreessen Horowitz (a16z Bio + Health) and ARCH Venture Partners. Liquid 2 Ventures is listed as a regional player.
Does Alix Ventures have an API?
No public API is recorded for Alix Ventures.
What industry is Alix Ventures in?
Alix Ventures's product category is Life Science Venture Capital. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 523940 and its SIC code is 6282.